Clinical Practice Guidelines

Call for submissions on draft consensus advisory documents for general practitioners and gynaecologists

The National Centre for Gynaecological Cancers, in conjunction with an expert reference group, is inviting submissions on its draft consensus advisory documents for general practitioners and gynaecologists:

Abnormal vaginal bleeding in pre and peri menopausal women: Investigations leading to a diagnosis of endometrial cancer

Vaginal bleeding in post menopausal women: Investigations leading to a diagnosis of endometrial cancer

These advisory documents have been developed in response to identified variations in the investigation of abnormal vaginal bleeding in pre, peri and post menopausal women which may indicate endometrial cancer.

There are currently no national, evidence-based clinical guidelines for endometrial cancer. Endometrial cancer is the most common invasive gynaecological cancer, affecting more than 1600 women and causing more than 200 deaths in 2003.  There is currently no effective screening procedure for early detection, and five year survival rates are low, particularly for women with advanced cancer.

How to make your submission:

Download the Submission Proforma and Supplementary Information.

You may make your submission in writing via email or fax. Please send you submission by post or email to:

Ella Curnow

Project Officer

National Centre for Gynaecological Cancers

PO Box 1201

Dickson ACT 2602

Ella.curnow@canceraustralia.gov.au

Closing date:

Your submission must be received by 30 September 2010

Phase 2 Clinical guidelines development

The Centre has recently commenced its second phase of clinical guideline development for the management of women with endometrial cancer. With a goal of building the capacity in clinical practice guideline development, the Centre will work in partnership with Cancer Council Australia to develop evidence based clinical practice guidelines for the management and treatment of endometrial cancer in the following four identified areas of priority:

• Early stage low-risk endometrial cancer

• Early stage high-risk endometrial cancer

• Metastatic endometrial cancer (both nodal and widespread)

• Recurrent endometrial cancer